Low-dose, off-label drotrecogin alfa (xigris) in severe sepsis.

نویسندگان

  • Shan Wang
  • Kristina Dabovic
  • Ruth S Spector
چکیده

OBJECTIVE In this article, we describe a successful low-dose, off-label usage of drotrecogin alfa (Xigris), given at 18 mcg/kg per hour, in a patient with severe sepsis who had an Acute Physiology and Chronic Health Evaluation II (APACHE II) score of 26 and multiorgan failure. PATIENT A 64-year-old man was admitted to the surgical intensive-care unit of Winthrop University Hospital in Mineola, New York. After undergoing small-bowel resection secondary to obstruction, he became severely septic. Because of his high risk of death (with an APACHE II score of 26 and two organ failures), he was initially treated with drotrecogin alfa 24 mcg/kg per hour, the dose approved by the U.S. Food and Drug Administration (FDA). Within four hours, his activated partial thromboplastin time became significantly prolonged from a baseline of 27.8 to 92.9 seconds, and he had coffee-ground nasogastric tube output. In light of signs of bleeding, drotrecogin alfa was temporarily discontinued. After 26 hours without further evidence of bleeding, drotrecogin alfa was administered at a lower dose of 18 mcg/kg per hour. The manufacturer's recommendation of 96 hours of infusion therapy was completed with the lower dosing. The patient's condition improved significantly, and eventually he was discharged home. CONCLUSION This case report demonstrates an alternative use of drotrecogin alfa at a lower dose of 18 mcg/kg per hour in a severely septic patient who could not tolerate the FDA-approved dose of 24 mcg/kg per hour because of bleeding.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany.

Drotrecogin alfa (activated) (Xigris; Eli Lilly and Company, Indianapolis, IN) significantly reduced mortality in severe sepsis in the PROWESS trial. We evaluate the cost-effectiveness of drotrecogin alfa (activated) as an adjunct to standard therapy from the German healthcare payer's perspective with respect to patients with 1) severe sepsis and 2) severe sepsis and multiple organ failure the ...

متن کامل

Drotrecogin alfa (activated), Xigris, label

DESCRIPTION Xigris (drotrecogin alfa (activated)) is a recombinant form of human Activated Protein C. An established human cell line possessing the complementary DNA for the inactive human Protein C zymogen secretes the protein into the fermentation medium. Fermentation is carried out in a nutrient medium containing the antibiotic geneticin sulfate. Geneticin sulfate is not detectable in the f...

متن کامل

COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) IN THE TREATMENT OF SEVERE SEPSIS WITH MULTIPLE ORGAN FAILURE Short title: cost-effectiveness of drotrecogin alfa

Objectives: To estimate the expected cost and clinical benefits associated with the use of drotrecogin alfa (activated) [Xigris; Eli Lilly and Company; Indianapolis, IN] in the French hospital setting. Methods: The PROWESS study results (1,271 patients with multiple organ failure) were adjusted to 9,948 hospital stays from a database of Parisian area intensive care units (ICUs) – the CubRea dat...

متن کامل

Heparin prophylaxis did not increase mortality and was beneficial in adults with sepsis receiving drotrecogin alfa.

M e t h o d s Design: Randomized, placebo-controlled, equivalence trial (Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis [XPRESS]). Allocation: {Concealed}†.* Blinding: Blinded (patients, {clinicians, and outcome assessors}†).* Follow-up period: 28 days. Setting: 224 sites in 20 countries in North, Central, and South America; Europe; Asia; and Australia. Patients: 1994 patients who ...

متن کامل

Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.

STUDY OBJECTIVE To gather additional 28-day all-cause mortality and safety data among adult patients with severe sepsis who were treated with drotrecogin alfa (activated). DESIGN Prospective, single-arm, multicenter clinical trial. SETTING Eighty-five study sites in the United States and two in Puerto Rico. PARTICIPANTS Adult patients (273 patients) with a diagnosis of severe sepsis, whic...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • P & T : a peer-reviewed journal for formulary management

دوره 33 8  شماره 

صفحات  -

تاریخ انتشار 2008